drugset / Trial / NCT06045299
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
RandomizedParallel-groupDouble-blindTreatment
Summary
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia
Timeline
- Start
- 2023-09-27
- Primary completion
- 2024-08-19
- Completion
- 2025-01-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aceclidine | Small molecule | — | Other |
| Subject | Brimonidine | Small molecule | — | Other |